Celia Camacho Toledano
Predoctoral researcher
Neuroinmuno-Repair Group (Lab i2-04; office i2-12)
National Hospital for Paraplegics-SESCAM
Toledo, Spain

1.-ACADEMIC DEGREES

-Bachelor of Biochemistry (2017). Castilla-La Mancha University. Toledo, Spain.

- Master´s degree in Immunology Research (2018). Complutense University of Madrid. Madrid, Spain.

2.- RESEARCH AND PROFESSIONAL EXPERIENCE

- **2017:** Undergraduate student. Neurodegenerative chemistry group. National Hospital for Paraplegics-SESCAM. Toledo, Spain.

- **2018:** Master student. Neuroinmuno-Repair group. National Hospital for Paraplegics-SESCAM. Toledo, Spain.

- **2019-2020:** Research fellow supported by private entities. Neuroinmuno-Repair group. National Hospital for Paraplegics-SESCAM. Toledo, Spain.

- **2020 to date:** PhD studentsupported by a competitive research fellowship (PFIS) from *Instituto de Salud Carlos III* **(FI19/00132)**. Neuroinmuno-Repair group. National Hospital for Paraplegics-SESCAM. Toledo, Spain.

3.- PUBLICATIONS

Original papers

2018

Doncel-Pérez, E., Aranaz, I., Bastida, A., Revuelta, J., ***Camacho, C.***, & Acosta, N. et al. 2018. Synthesis, physicochemical characterization and biological evaluation of chitosan sulfate as heparan sulfate mimics. *Carbohydrate Polymers*, vol. 191, 225-233 (2018). https://doi.org/10.1016/j.carbpol.2018.03.036

2021

Hélie, P* ., ***Camacho-Toledano, C****,., Lesec, L., Seillier, C., Miralles, A.J., Ortega, MC., Guerit, S., Lebas, H., Bardou, I., Vila-del Sol, V., Vivien, D., Le Mauff, B., Clemente, D [#]., Docagne, F[#]., Toutirais, O[#]. Tissue plasminogen activator worsens experimental autoimmune encephalomyelitis by complementary actions on lymphoid and myeloid cell responses. *J Neuroinflammation* 18**,** 52 (2021).
https://doi.org/10.1186/s12974-021-02102-5

*[#]Similar contribution

4.- SCIENTIFIC COMMUNICATIONS IN NATIONAL/INTERNATIONAL CONFERENCES

2017

J.Revuelta, E.Doncel-Pérez, ***C. Camacho-Toledano***, E. Martínez, A. Bastida, L. Garrido, E. García-Junceda, A.Fernández-Mayoralas. **Effect of new chemically sulfated chitosan polysaccharides in neural cell differentiation**. 03/2017. 13th International Conference of the European Chitin Society- 8th Symposium of the Iberoamerican Chitin Society. Sevilla, Spain. Poster.

2019

I. Sánchez-de Lara, R. Lebrón-Galán, I. Machín, ***C. Camacho-Toledano***, MC. Ortega, D. Clemente. **The peripheral blood content of myeloid-derived suppressor cells is a bioindicator of a greater capacity for spontaneous remyelination in multiple sclerosis**. 07/2019. XIV European Meeting on Glial Cells in Health and Disease. Oporto, Portugal. Congress communication.

I. Sánchez-de Lara, R. Lebrón-Galán, I. Machín, ***C. Camacho-Toledano***, MC. Ortega, D. Clemente. **Myeloid-derived suppressor cell peripheral load can predict a greater endogenous remyelination capacity in the murine model of multiple sclerosis**. 09/2019. 18th National meeting of the Spanish society of Neuroscience. Santiago de Compostela, Spain. Congress communication.

R. Lebrón-Galán, MC. Ortega, I. Sánche-de Lara, I. Pérez-Molina, V. Quintanero, MR. García-Montero, ***C. Camacho-Toledano***, I. Machín-Díaz, D. Clemente. **The peripheral immune system as biomarker of the disease severity and tissue damage extent in multiple sclerosis**. 2019. 18th National meeting of the Spanish society of Neuroscience. Santiago de Compostela, Spain. Congress communication.

R. Lebrón-Galán, I.Sánchez-de Lara, M. Nieto-Díaz, ***C. Camacho-Toledano***, I. Machín-Díaz, MC. Ortega, D. Clemente. **Peripheral myeloid-derived suppressor cells: a new tool to predict the severity of the clinical course and tissue damage extent in multiple sclerosis**. 2019. 35thCongress of the European Committee for Treatment and Research in Multiple Sclerosis. Stockholm, Sweden. Congress communication.

2020

C. Camacho-Toledano, R. Lebrón-Galán, I. Machín-Díaz, J. García-Arocha, MC. Ortega, D. Clemente. **Myeloid-Derived Suppressor Cells associated to a mild disease course are good bioindicators of a higher remyelinating capability in Multiple Sclerosis**. 09/2020. 8th Joint ACTRIMS-ECTRIMS Meeting. Washintong D.C, EE.UU. Poster.

C. Camacho-Toledano, R. Lebrón-Galán, I. Machín-Díaz, J. García-Arocha, MC. Ortega, D. Clemente. **NG2 cells and the immunoregulatory environment in the CNS: key factors for multiple sclerosis severity**. 11/2020. 3rd Symposium on Physiology and Pathology of Neuroglia. Queretaro, Mexico. Poster.

5.- GRANTED RESEARCH PROJECTS

- Competitive R&D projects

- **2017-2021:Grupo de la Red Española de Esclerosis Múltiple**. *Programa Retics. Instituto de Salud Carlos III. Acción Estratégica en Salud 2016. Ministerio de Economía, Industria y Competitividad*. **Total amount:** 112.500€. **Role**: Associated Research.**PI:** Diego Clemente

- **2019-2021**: **Estudio del potencial de las células mieloides supresoras como bioindicadores de la severidad del curso clínico y de respuesta al tratamiento en Esclerosis Múltiple**. *Acción Estratégica en Salud 2018. Ministerio de Ciencia, Universidad e Innovación.* **Total amount:** 255.310€. **Role:** Associated Research. **PI:** Diego Clemente

- **2020-2023: Análisis del componente inmuno-regulador de la respuesta inmune periférica y central como biomarcador de severidad del curso clínico en Esclerosis Múltiple**. *Fundación Merck Salud 2020.* **Total amount:** 30.000€. **Role**: Associated Research. **PI:** Diego Clemente

- Projects supported by private entities

- **2017: Células mieloides supresoras: diana terapéutica endógena para el tratamiento de la esclerosis múltiple.** Fundación Galletas Coral; Aciturri Aeronáutica S.L;Vesuvius Ibérica; Embutidos y Jamones España e Hijos. **Total amount:** 20,250 €.**Role:** Associated Research. **PI:** Diego Clemente

- **2018: Estudio de las células mieloides supresoras como biomarcadores del curso clínico de la esclerosis múltiple y su implicación en estrategias reparadoras de la vaina de mielina dañada.** Asociación de Esclerosis Múltiple de Toledo (ADEM-TO). **Total amount:** 31,768 €.**Role:** Associated Research. **PI:** Diego Clemente

- **2020: Analysis of the effect of Evobrutinib over Myeloid-Derived Suppressor Cells.** Merck Serono EMB. **Total amount:** 200,000 €.**Role:** Associated Research.**PI:** Diego Clemente